Notice of Contract Award - Orexo US, Inc.
Closed Special Notice Posted
- Solicitation number
- BARDA-BAA-OrexoNotice
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- Morristown, New Jersey 07960, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response has published a contract award notice for Orexo US, Inc. under contract number 75A50125C00010. This award notice announces the completion of a competitive procurement process that resulted in a significant contract valued at $67,863,006 awarded on September 24, 2025. The contract focuses on the clinical development of OX390 (atipamezole), a pharmaceutical compound designed to serve as an alpha-2 agonist reversal agent. The project addresses the growing public health challenge of overdoses involving xylazine, medetomidine, and other alpha-2 agonists that are increasingly found in combination with illicit fentanyl (IMF), particularly in cases where naloxone provides only partial resuscitation effectiveness.
The primary objective of this contract is to advance the clinical development of OX390 as a medical countermeasure to reverse the sedative effects of alpha-2 agonists in human overdose scenarios. Since this is an award notice rather than a solicitation, no contractor eligibility criteria or participation requirements are applicable, as the competitive selection process has already concluded with Orexo US, Inc. as the successful bidder. The contract was originally solicited under BAA-23-100-SOL-00004 and falls under NAICS code 541714 for Research and Development in Physical, Engineering, and Life Sciences. The work encompasses six contract line items (CLINs 0001-0006) and represents a critical component of the federal government's broader preparedness and response strategy to address the evolving opioid crisis and emerging threats in the illicit drug supply.
Notice text
Award Notice for Orexo US, Inc. (Contract 75A50125C00010). Clinical development of OX390 (atipamezole) as an α2 agonist reversal agent for human use to counteract the sedative effects of xylazine, medetomidine, and other α2 agonists that are increasingly found in combination with IMF.
Files
| File | Type | Posted |
|---|---|---|
| SAM Post Award Notification - Orexo.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity